⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetaldehyde SCHEMBL18398677 | 0.90 | GAPDH (0.33) | — | |
| SCHEMBL10126328 | 0.83 | SMN1; SMN2 (0.36) | — | |
| SCHEMBL1133258 | 0.78 | CHRM1 (0.46) | — | |
| SCHEMBL2884275 | 0.77 | TSHR (0.36) | — | |
| SCHEMBL9599979 | 0.77 | TSHR (0.36) | — | |
| SCHEMBL4642136 | 0.77 | — | — | |
| SCHEMBL2884280 | 0.77 | TSHR (0.36) | — | |
| Oxalic Acid SCHEMBL28235580 | 0.77 | OR51E2 (0.48) | — | |
| SCHEMBL15355768 | 0.75 | — | — | |
| SCHEMBL193026 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3321686-B1 | BIOMARKERS RELATED TO INSULIN RESISTANCE PROGRESSION AND METHODS USING THE SAME | METABOLON INC (US) | 2024-03-13 | — | — | EP | claimed |
| EP-3321686-A1 | BIOMARKERS RELATED TO INSULIN RESISTANCE PROGRESSION AND METHODS USING THE SAME | Metabolon, Inc. (US) | 2018-05-16 | — | — | EP | claimed |
| EP-2951313-B1 | BIOMARKERS RELATED TO INSULIN RESISTANCE PROGRESSION AND METHODS USING THE SAME | METABOLON INC (US) | 2018-03-07 | — | — | EP | claimed |
| US-9910047-B2 | Biomarkers related to insulin resistance progression and methods using the same | METABOLON, INC. (US) | 2018-03-06 | — | — | US | claimed |
| US-9523105-B2 | Fermentation route for the production of levulinic acid, levulinate esters and valerolactone and derivatives thereof | ARZEDA CORPORATION (US) | 2016-12-20 | — | — | US | claimed |
| US-20150362510-A1 | Biomarkers Related to Insulin Resistance Progression and Methods Using the Same | METABOLON, INC. | 2015-12-17 | — | — | US | claimed |
| EP-2951313-A1 | BIOMARKERS RELATED TO INSULIN RESISTANCE PROGRESSION AND METHODS USING THE SAME | Metabolon, Inc. (US) | 2015-12-09 | — | — | EP | claimed |
| WO-2014120449-A1 | BIOMARKERS RELATED TO INSULIN RESISTANCE PROGRESSION AND METHODS USING THE SAME | METABOLON, INC. (US) | 2014-08-07 | — | — | WO | claimed |
| US-7309719-B1 | Storage stability; gabapentin and pregabalin, and neutral alpha -amino acid | WARNER LAMBERT COMPANY, LLC (US) | 2007-12-18 | — | — | US | claimed |
| EP-1077692-B1 | AMINO ACID STABILIZED GABAPENTIN AND PREGABALIN PREPARATIONS AND PROCESS FOR PREPARING THE SAME | WARNER LAMBERT CO (US) | 2004-07-28 | — | — | EP | claimed |
| WO-1999059573-A9 | STABILIZED PHARMACEUTICAL PREPARATIONS OF GAMMA-AMINOBUTYRIC ACID DERIVATIVES AND PROCESS FOR PREPARING THE SAME | WARNER LAMBERT CO (US) | 2000-05-04 | — | — | WO | claimed |
| US-12383522-B2 | Baclofen formulations and methods of minimizing patient exposure to metabolite variations | AMNEAL PHARMACEUTICALS LLC (US) | 2025-08-12 | — | — | US | disclosed |
| US-11931328-B2 | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives | AMNEAL PHARMACEUTICALS LLC (US) | 2024-03-19 | — | — | US | disclosed |
| US-20240082193-A1 | BACLOFEN FORMULATIONS AND METHODS OF MINIMIZING PATIENT EXPOSURE TO METABOLITE VARIATIONS | AMNEAL PHARMACEUTICALS LLC (US) | 2024-03-14 | — | — | US | disclosed |
| EP-3321686-B1 | BIOMARKERS RELATED TO INSULIN RESISTANCE PROGRESSION AND METHODS USING THE SAME | METABOLON INC (US) | 2024-03-13 | — | — | EP | disclosed |
| WO-2006014353-A2 | GLYCOGEN OR POLYSACCHARIDE STORAGE DISEASE TREATMENT METHOD | BAYLOR RESEARCH INSTITUTE (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20060004099-A1 | Glycogen or polysaccharide storage disease treatment method | BAYLOR RESEARCH INSTITUTE (US) | 2006-01-05 | — | — | US | disclosed |
| EP-1077692-B1 | AMINO ACID STABILIZED GABAPENTIN AND PREGABALIN PREPARATIONS AND PROCESS FOR PREPARING THE SAME | WARNER LAMBERT CO (US) | 2004-07-28 | — | — | EP | disclosed |
| JP-2000247876-A | GLUTATHIONE BIOSYNTHESIS INHIBITOR | ASAHI BREWERIES LTD | 2000-09-12 | — | — | JP | disclosed |
| WO-1999059573-A9 | STABILIZED PHARMACEUTICAL PREPARATIONS OF GAMMA-AMINOBUTYRIC ACID DERIVATIVES AND PROCESS FOR PREPARING THE SAME | WARNER LAMBERT CO (US) | 2000-05-04 | — | — | WO | disclosed |